GSK stock trades at GBp 1,877 while Berenberg lifts target to GBp 2,200

Published on 09/25/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock delivered Q2 turnover of GBP 8.409 billion, up 5 percent, on July 28, 2026. Core EPS reached GBp 50.5 versus GBp 46.5 a year earlier.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK stock (ISIN GB0009252882) stood at GBp 1,877.00 on the London Stock Exchange on September 25, 2026, down 0.48 percent from the GBp 1,886.00 prior close. The key analyst signal came on September 15, 2026, when Yahoo Finance reported that Berenberg upgraded GSK from Hold to Buy and lifted its target from GBp 2,000 to GBp 2,200.

Berenberg raises its target

The target increase gives the latest analyst view a clear numerical reference. Berenberg analyst Kerry Holford cited GSK's business-development activity and pipeline momentum, while the target moved 10 percent above the previous GBp 2,000 level, according to Yahoo Finance.

Q2 turnover grows 5 percent

GSK's second-quarter 2026 turnover reached GBP 8.409 billion, up 5 percent from Q2 2025. The total operating profit was GBP 481 million, down 76 percent, while total EPS was GBp 10.8, down 69 percent, in the results reported on July 28, 2026, and detailed in a September 8, 2026 filing by StockTitan.

Specialty medicines lead growth

The operating mix explains why the headline turnover growth and the profit figures point in different directions. Specialty Medicines turnover rose 14 percent to GBP 3.782 billion, Vaccines turnover increased 9 percent to GBP 2.284 billion, and General Medicines declined 9 percent to GBP 2.343 billion, according to StockTitan. Core EPS was GBp 50.5, compared with GBp 46.5 in Q2 2025, an increase of 8.6 percent.

Stock remains below yearly high

The LSE quote was 17.75 percent below GSK's 52-week high of GBp 2,282.00 and above the 52-week low of GBp 1,455.00 on September 25, 2026. Trading volume was 3.57 million shares, placing the session in a broader valuation context while the analyst target provides a separate benchmark.